[{"id":"c56c0875-2077-4738-8cc2-b258916ee607","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406949","created_at":"2021-01-18T16:48:34.491Z","updated_at":"2024-07-02T16:36:10.175Z","phase":"Phase 1","brief_title":"MGD009/MGA012 Combination in Relapsed/Refractory Cancer","source_id_and_acronym":"NCT03406949","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" PD-L1 expression • CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2022","study_completion_date":" 04/27/2022","last_update_posted":"2022-05-19"}]